Justin F Gainor MD

PubMed

• 27 citations
  Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
  H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro
  Annals of Oncology. 2023-02-01
• 125 citations
  Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
  F Griesinger, G Curigliano, M Thomas, V Subbiah, C S Baik
  Annals of Oncology. 2022-11-01
• 33 citations
  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
  Sara E Schad, Andrew Chow, Levi Mangarin, Heng Pan, Jiajia Zhang
  The Journal of Experimental Medicine. 2022-06-06

Journal Articles

• Differential Expression of PD-L1 and IDO1 in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas  
  M Lisa Zhang, Justin F Gainor, Meghan J Mooradian, Nature
• Oxford University Press Has Registered This DOI Pre-Publication  
  R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Abstracts/Posters

• A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
  Justin Gainor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSC... 
  2019 ASCO Annual Meeting - 6/1/2019
• Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Immunotherapy for Oncogen... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018